MTOR and facioscapulohumeral muscular dystrophy: Additionally, we show that these compounds function through an mTor/AKT-independent mechanism that results in activation of cellular autophagy, thereby demonstrating that targeting both mTor-dependent and mTor-independent biochemical pathways are viable approaches for FSHD therapeutic development, and specifically identifying autophagy as a novel target for therapies.